Vivani Medical Reports Q1 Results, Secures $9.7M Capital, Extends Runway to Mid-2027, and Advances SLIM-1 Clinical Trial
VANI sits 26% above its 52-week low of $0.923.
Summary
Vivani Medical reported its first-quarter 2026 financial results, including an increased net loss but an improved per-share loss, while successfully raising $9.7 million to extend its cash runway through mid-2027. The company also confirmed its lead clinical trial is on track and is pursuing a spin-off of its neuromodulation subsidiary, Cortigent.
Key Events · Earnings and Guidance · VANI
-
First Quarter 2026 Financial Results
Vivani Medical reported a net loss of $6.8 million for Q1 2026, compared to $6.3 million in Q1 2025. However, net loss per common share improved to $(0.08) from $(0.11) year-over-year.
-
Extended Cash Runway
The company holds $28 million in cash, cash equivalents, restricted cash, and capital commitments as of March 31, 2026, expected to fund operations through the first half of 2027.
-
Successful Capital Raise
Vivani raised $9.7 million in financing activities during Q1 2026, including $2.2 million from a registered direct offering and $7.6 million from other securities purchase agreements.
-
Clinical Trial Progress
Initiation of the SLIM-1™ clinical trial, a Phase 1 study of its NPM-139 semaglutide implant for chronic weight management, is on track for mid-year 2026, with top-line results anticipated by year-end.
Analysis · VANI · Industrial Applications And Services
This filing provides a comprehensive update on Vivani Medical's financial health and pipeline progress. The successful capital raise of $9.7 million in Q1 significantly bolsters the company's cash position, extending its operational runway through the first half of 2027. This financial stability is critical for a clinical-stage biopharmaceutical company, enabling it to fund ongoing research and development. The confirmation that the SLIM-1 Phase 1 clinical trial is on track for mid-year initiation, with results expected by year-end, is a key value driver for the company's lead semaglutide implant program. Additionally, plans to spin off Cortigent Inc. could unlock further value for shareholders.
At the time of this filing, VANI was trading at $1.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $98.2M. The 52-week trading range was $0.92 to $1.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.